Sorbitol Is a Severity Biomarker for <scp>PMM2‐CDG</scp> with Therapeutic ImplicationsAnna N. Ligezka, Éva Morava, William Brucker et al.|Annals of Neurology|2021Cited by 57
Tracer metabolomics reveals the role of aldose reductase in glycosylationSilvia Radenkovic, Éva Morava|Cell Reports Medicine|2023Cited by 32
SSR4-CDG, an ultra-rare X-linked congenital disorder of glycosylation affecting the TRAP complex: Review of 22 affected individuals including the first adult patientChristin Johnsen, Éva Morava, Nazi Tabatadze et al.|Molecular Genetics and Metabolism|2024Cited by 17
Novel insights into the phenotype and long-term D-gal treatment in PGM1-CDG: a case seriesSilvia Radenkovic, Éva Morava, Christin Johnsen et al.|Therapeutic Advances in Rare Disease|2023Cited by 11